CTRI/2024/06/069519
Not yet recruiting
未知
Clinical study to assess the efficacy & safety of celery extract capsules in the management of knee osteoarthritis. - NA
Phytoveda Pvt Ltd0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: M179- Osteoarthritis of knee, unspecified
- Sponsor
- Phytoveda Pvt Ltd
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Adults aged 40 to 65 years (both inclusive), of both sexes, with a Body Mass Index (BMI) not more than 30\.00 kg/m²; 2\.Confirmed diagnosis of knee osteoarthritis as per clinical ACR (American College of Rheumatology) criteria – Clinical OA of the knee is defined as knee pain and at least three out of six of the following criteria: age more than 50 years old, morning stiffness less than 30 minutes, crepitus on knee motion, bony tenderness, bony enlargement, no palpable warmth; 3\.Participants with a minimum pain visual analog scale (VAS) score more than 4 on walking in one or both knees during the 24 hrs. preceding recruitment; 4\.Participant ambulant and requiring treatment with an anti inflammatory drug and not receiving regular anti inflammatory or analgesic drugs or not satisfied with drugs being taken and seek a change; 5\.Participants taking analgesics ready for the washout period of at least 3 days (or longer depending on the pharmacokinetic of drug) before starting the study intervention; 6\.Participants willing to come for regular follow up visits; 7\.Participants can walk and give both verbal and written information regarding the study.
Exclusion Criteria
- •1\.Known history of hypersensitivity to herbal extracts or dietary supplements;
- •2\.Pregnant women, lactating women, and women of child bearing potential not following adequate contraceptive measure, women who were found positive for urine pregnancy test;
- •3\.Non degenerative joint diseases or other joint degenerative diseases (musculoskeletal disorders) which will interfere with the evaluation of OA (Rheumatoid arthritis, active gout, recent joint trauma (target joint), or joint infection);
- •4\.Participants incapacitated or bound to wheelchair or bed and unable to carry out self\-care activities;
- •5\.Treatment with intra\-articular injection of corticosteroids into the knee within 3 months preceding study;
- •6\.Ongoing treatment with anticoagulants, hydantoin, lithium, steroids, methotrexate, and colchicine;
- •7\.Evidence of several renal, hepatic, or hematopoietic disease or severe cardiac insufficiency as revealed by laboratory investigations;
- •8\.Participant with congestive heart failure;
- •9\.Ayurvedic formulation or any form of CAM (Complimentary Alternative Medicine) therapy in the preceding 2 months;
- •10\.Administration of intra\-articular steroids in the past 3 months or hyaluronic acid in the last 9 months;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Photodynamic diagnosis using 5-ALA for biliary pancreatic cancerBiliary pancreatic cancerJPRN-jRCTs061210042Isomoto Hajime62
Not yet recruiting
Not Applicable
Efficacy and safety of Photodynamic diagnosis using aminolaevulinic acid for oral cancer patients.JPRN-jRCTs031230192Satomura Kazuhito80
Completed
Phase 3
Efficacy and safety of Dapoxetine Hydrochloride Tablet in treatment of Premature EjaculatioCTRI/2010/091/000660Emcure Pharmaceuticals Ltd, Pune172
Unknown
Phase 3
Clinical trial of tablet containg two medicines - Dapoxetine and Sildenafil - for the treatment of co-existing Erectile Dysfunction and Premature Ejaculation.Health Condition 1: null- Co-existing Erectile Dysfunction and Premature EjaculationCTRI/2012/01/002370Emcure Pharmceuticals Ltd Pune200
Recruiting
Phase 2
Clinical study on Vimosa Softgel in vaginal dryness and vaginal prolapseCTRI/2024/05/067423Abhinav Health Care Products Pvt Ltd